Siteman Kids at St. Louis Children’s Hospital is the No. 1 pediatric cancer program in the St. Louis region, according to U.S. News & World Report for 2025-26. It draws on the Siteman Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in Missouri, and is the only NCI-funded pediatric cancer center to provide experimental therapy in the state. Siteman Kids is one of only 21 member institutions in the Children’s Oncology Group’s Pediatric Early Phase Clinical Trial Network, giving patients access to some of the newest pediatric cancer therapies before they are widely available. Its stem cell transplant and cellular therapy program uses lower doses of chemotherapy when possible to treat lymphomas, leukemias, sickle cell disease, immunodeficiencies and solid tumors, while targeted options such as proton beam therapy, Gamma Knife radiosurgery and intensity modulated radiation therapy help minimize damage to healthy tissue. The program also offers CAR T-cell and other cellular immunotherapies, MIBG therapy for high-risk neuroblastoma, and genomic medicine to design treatment plans targeting the specific genes driving each child’s cancer. Its chemotherapy-ordering program has been recognized as a best practice by The Joint Commission, and its physicians partner daily with researchers from Washington University School of Medicine to develop and test new treatments. After treatment, patients are followed through the childhood cancer survivorship program and, in adulthood, the lifelong outcomes clinic that monitors for long-term side effects of cancer therapy.
